Super-oxidized microcyn technology in lower-extremity wounds: Introduction and early experience

Wounds

Volumn 18, Issue 1 SUPPL., 2006, Pages 3-6

  Allie, David E ^a  

^a Cardiovascular Institute of the South   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33644534885     PISSN: 10447946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. US Department of Health and Human Services. National Center for Health Statistics. National Hospital Discharge Survey: Annual Summary with Det Arnold Publication; 1996:162-175.
2. Hobson RW 2nd, Lynch TG, Jamil Z, et al. Results of revascularization and amputation in severe lower extremity ischemia: a five-year clinical experience. J Vasc Surg. 1985;2(1):174-185.
3. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31(1 Pt 2):S1-S296.
4. Gregg RO. Bypass or amputation? Concomitant review of bypass arterial grafting and major amputations. Am J Surg. 1985;149(3):397-402.
5. Mackey WC, McCullough JL, Conlon TP, et al. The costs of surgery for limb-threatening ischemia. Surgery. 1986;99(1):26-35.
6. Raviola CA, Nichter LS, Baker JD, et al. Cost of treating advanced leg ischemia. Bypass graft vs primary amputation. Arch Surg. 1988;123(4):495-496.
7. Paaske WP, Laustsen J. Femorodistal bypass grafting: quality of life and socioeconomic aspects. Eur J Vasc Endovasc Surg. 1995;10(2):226-230.
8. Wolfe JH, Wyatt MG. Critical and subcritical ischaemia. Eur J Vasc Endovasc Surg. 1997;13(6):578-582.
9. Pentecost MJ, Criqui MH, Dorros G, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vascular Surgery, Clinical Cardiology, and Epidemiology and Prevention, the American Heart Association. Circulation. 1994;89(1):511-531.
10. Muradin GS, Myriam Hunink MG. Cost and patency rate targets for the development of endovascular devices to treat femoropopliteal arterial disease. Radiology. 2001;218(2):464-469.
11. Muradin GS, Bosch JL, Stijnen T, Hunink MG. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology. 2001;221(1):137-145.
12. Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22(3):382-387.
13. Edmonds ME, Blundell MP, Morris ME, et al. Improved survival of the diabetic foot: the role of a specialized foot clinic. Q J Med. 1986;60(232):763-771.
14. Dang CN, Prasad YD, Boulton AJ, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med. 2003;20(2):159-161.
15. Wagner A, Reike H, Angelkort B. Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant Staphylococcus aureus infections. Dtsch Med Worchenschr. 2001;126(48):1353-1356.
16. Theta Reports. Advanced wound care biologics: world market analysis. August 1, 2002. Available at: http://www.marketresearch.com/product/display.asp? productid=801249&SID=84612660-339803724-290187384. Accessed December 19, 2005.
17. Motta G. "The first 60 days of PPS: managing wound care medical supplies." The Remington Report. Nov/Dec. 2000. http://www.woundcare.org/ newsvol5n3/ar10.htm.
18. Lyder CH, Shannon R, Empleo-Frazier O, et al. A comprehensive program to prevent pressure ulcers in long-term care: exploring costs and outcomes. Ostomy Wound Manage. 2002;48(4):52-62.
19. US Census Bureau. Statistical Abstract of the United States: 1996. 116th ed. US Department of Commerce, Washington, DC; 1996.